Home Healthcare IT europe-lung-cancer-screening-software-market

Healthcare IT

Image

Europe Lung Cancer Screening Software Market – Industry Trends and Forecast to 2029

  • Healthcare IT
  • Published Report
  • Aug 2022
  • Europe
  • 350 Pages
  • No of Tables: 330
  • No of Figures: 27

Europe Lung Cancer Screening Software Market, By Mode of Delivery (Cloud Based Solutions, On-Premise Solutions and Web Based Solutions), Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACs, Practice Management and Audit Log Tracking), Type (Computer-Assisted Screening and Traditional Screening), Application (Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Platform (Standalone and Integrated), Purchase Mode (Institutional and Individual), End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Third Party Distributors) - Industry Trends and Forecast to 2029.

Europe Lung Cancer Screening Software Market

Europe Lung Cancer Screening Software Market Analysis and Size

Control of lung cancer death rates is one of the major concerns for healthcare facilities. Public and private organizations are taking initiatives to launch screening programs to control the death rates. In addition, companies are launching advanced software to ease the management of patients’ data and provide better care with strict data privacy guidelines.

Europe Lung Cancer Screening Software Market

Europe Lung Cancer Screening Software Market

Increase in prevalence of lung cancer, rising awareness among people about lung cancer, increasing government initiatives, and growing number of screening programs are some of the major factors driving the growth of the market. In addition, advancement in Artificial Intelligence (AI)-based solutions and strategic initiatives by key market players are creating opportunities in the field of lung cancer screening software.

However, data privacy issues and lack of unskilled labor are expected to hamper the market growth in the forecast period.

Data Bridge Market Research analyzes that the Europe lung cancer screening software market is expected to reach the value of USD 27,518.34 thousand by 2029, at a CAGR of 19.6% during the forecast period. Cloud based solutions accounts for largest mode of delivery segment in the market. The market report also covers pricing analysis, patent analysis, and technological advancements in depth.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019-2014)

Quantitative Units

Revenue in USD Thousand, Pricing in USD

Segments Covered

By Mode of Delivery (Cloud Based Solutions, On-Premise Solutions and Web Based Solutions), Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACs, Practice Management and Audit Log Tracking), Type (Computer-Assisted Screening and Traditional Screening), Application (Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)), Platform (Standalone and Integrated), Purchase Mode (Institutional and Individual), End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender and Third Party Distributors)

Countries Covered

Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium and rest of Europe

Market Players Covered

PenRad Technologies Inc., Koninklijke Philips N.V, Volpara Health Limited, Thynk Health, Nuance Communications, Inc., Siemens Healthcare GmbH, MyCareWare, Inc., MagView, MeVis Medical Solutions AG, Canon Medical Informatics, Inc., General Electric Company, Epic Systems Corporation, Lungview, Eon, Medtronic, Coreline Soft Co., Ltd., Optellum Ltd, HealthMyne, Oncocyte Corporation, Genesystem, REVEALDX, FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Median Technologies, AstraZeneca, and Aidence.com

Market Definition

Lung cancer screening is identifying stages of lung cancer using different technologies and software. Lung cancer screening using CT is the most recommended technique for screening lung cancer. The rising use of this technique is expected to accelerate the need for advanced software for lung cancer screening. This software helps to manage patients’ participation in lung screening programs and provides an efficient way for healthcare professionals to collect, curate, and transfer data to clinicians and patients. In addition, this software enables in the identification of patients at risk and automates the flow of data with integrated electronic health records.

Europe Lung Cancer Screening Software Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints and challenges. All of this is discussed in detail below:

Drivers

  • Increase in prevalence of lung cancer cases globally

Lung cancer is a leading cause of death in men and women. According to World Cancer Research Fund International, lung cancer is the second most common cancer worldwide. It is the most common cancer in men and second most common in women. There were more than 2.2 thousand new cases of lung cancer in 2020. Increasing prevalence of lung cancer cases creates need to adopt lung cancer screening software for early diagnosis and acts as a driving factor for the market growth.

  • Increase in awareness regarding the benefits of early diagnosis and frequent screening

The rising awareness programs of lung cancer by public, non-profit, and private organization are anticipated to boost the market growth. These initiatives aim to prevent diseases, reduce stigma and prejudice, and promote research. The awareness among the population regarding lung cancer has increased. Because there are many awareness programs by different organizations, people know about lung cancer that can be cured if diagnosed early. Thus, raising awareness among populations is driving the market growth.

  • Government initiatives were undertaken to implement screening programs for various diseases

The burden of cancer continues to increase globally and has great financial, emotional, and physical stress on health systems, products, families, and individuals. In countries with strong health systems, the survival rate of many types of cancer is improved due to survivorship, quality care, increased awareness, and accessible early detection. Centers for Disease Control and Prevention, U.S., tribes, and the U.S.-Pacific islands and territories through the National Comprehensive Cancer Control Program (NCCCP) are to form or support alliances to combat cancer in their communities. Due to these initiatives, more audiences are educated and more consciously dispersed, pushing the global audience to take further precautions and practice preventive examinations, promoting the market.

  • Growing number of screening programs across the globe

Screening is an effective method of detecting early-stage cancer. There is an increasing trend in lung cancer incidences in developing countries. Although there are regular recommendations for screening for breast and cervical cancer, it is not the same in the case of lung cancer. Most countries or institutions have initiated the feasibility and disease screening of Low-Dose Computed Tomography (LDCT) for lung cancer. The increasing number of lung cancer screening has created an opportunity for the market players. Hence, the increasing diagnostic rate acts as a driving factor for market growth.

Opportunity

  • Rising collaborations, mergers & acquisitions among the market players

The companies operating in the market are adopting several strategies, including mergers and acquisitions, product launches, agreements, pipeline development, collaborations, and market expansion among others, to boost their business in various dimensions. These strategic decisions by the companies are expected to offer significant opportunities for the market players operating in the market.

Restraint/Challenge

  • Issues related to the availability of software

There are certain issues/barriers related to effective and efficient lung cancer screening and the availability of lung cancer screening software in developing nations. Issues are competing demands for time, knowledge about lung cancer screening, evolving attitudes about the effectiveness of screening, nihilism related to historically poor lung cancer treatment outcomes, and limited training and requirement approval for local authorities or country medical device regulatory body. All these issues delay launches and availability of the product. Also, the demand for lung cancer screening software is hampered due to technical issues related to the available software thereby, acting as a restraint for market growth.

Post-COVID-19 Impact on Europe Lung Cancer Screening Software Market

COVID-19 created a major impact on various industries as almost every country opted for the shutdown of every facility except the ones dealing in the essential goods segment. The government took some strict actions such as the shutdown of facilities and sale of non-essential goods, blocking international trade, and many more to prevent the spread of COVID-19. The only business which was running during this pandemic situation was the essential services that were allowed to open and run the processes.

COVID-19 created new and unfamiliar challenges for healthcare providers to deliver patient care. Many non-essential but important services such as lung cancer screening were temporarily suspended to protect the health of staff and patients. Healthcare institutions faced unprecedented challenges regarding scheduling, patient monitoring, and follow-up of patient-service communication to ensure continuity of care during COVID-19 and when services could be continued safely. COVID-19 created new challenges for lung cancer screening programs, in many cases, delaying screening by several months and creating more difficulties for management and scheduling teams. Although the COVID-19 crisis shed new light on the importance of respiratory assistance, it will hopefully have a major impact on reducing stigma of screening for cancer. There are more than 10,000,000 eligible patients in the U.S. who are eligible for lung cancer screening, less than 5 percent of whom are actively enrolled in the screening program. COVID-19 created a negative impact on the market.

However, the lung cancer screening software companies are struggling and continuously taking different strategic decisions to control the situation. The players are involved in strategic activities such as partnerships, collaborations, and mergers & acquisitions among others to improve the technology involved in the market. With this, the companies will bring advanced and accurate solutions to the market. In addition, the government initiatives to boost digitization across industries have also led to market growth.

Recent Developments

  • In July 2022, GE Healthcare launched their latest product and most advanced ultrasound, the next-generation Voluson Expert 22. This latest addition to GE Healthcare’s award-winning Women’s Health portfolio utilizes graphic-based beam former technology, which produces higher quality images and offers greater flexibility in imaging functions. With this product, the company made its position much stronger in the area of products and service providers to healthcare institutions.
  • In October 2021, Thynk Health announced a partnership with Infervision, to fight lung cancer with the world’s most advanced technologies. It offers an opportunity for lung cancer screening and pulmonary nodule management. With this partnership, the company increased its market presence.

Europe Lung Cancer Screening Software Market Scope

Europe lung cancer screening software market is segmented into eight notable segments based on mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Mode of Delivery

  • Cloud Based Solutions
  • On-Premise Solutions
  • Web Based Solutions

On the basis of mode of delivery, the market is segmented into cloud based solutions, on-premise solutions, and web based solutions.

Product

  • Lung Cancer Screening Radiology Solution
  •  Lung Cancer Screening Patient Management Software
  •  Nodule Management Software
  •  Data Collection and Reporting
  •  Patient Coordination and Workflow 
  •  Lung Nodule Computer Aided Detection
  •  Pathology and Cancer Staging
  •  Statistical Audit Reporting
  •  Screening PACS
  •  Practice Management 
  •  Audit Log Tracking  

On the basis of product, the market is segmented into lung cancer screening radiology solution, lung cancer screening patient management software, nodule management software, data collection and reporting, patient coordination and workflow, lung nodule computer aided detection, pathology and cancer staging, statistical audit reporting, screening PACS, practice management, and audit log tracking.

Type

  • Computer-Assisted Screening
  •  Traditional Screening

On the basis of type, the market is segmented into computer-assisted screening and traditional screening.

Application

On the basis of application, the market is segmented into Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Platform

  • Standalone
  • Integrated

On the basis of platform, the market is segmented into standalone and integrated.

Purchase Mode

  • Institutional
  • Individual

On the basis of purchase mode, the market is segmented into individual and institutional.

End User

On the basis of end user, the market is segmented into hospitals, oncology centers, ambulatory surgical centers, and others.

By Distribution Channel

  • Direct Tender
  • Third Party Distributors

Lung Cancer Screening Software

On the basis of distribution channel, the market is segmented into direct tender and third party distributors.  

Europe Lung Cancer Screening Software Market Regional Analysis/Insights

The Europe lung cancer screening software market is analyzed and market size insights and trends are provided based on mode of delivery, product, type, application, platform, purchase mode, end user, and distribution channel.as referenced above.

The countries covered in this market report are Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium and rest of Europe. Germany dominates the market as lung cancer is the leading cause of cancer death in Europe which creates a need to adopt lung cancer screening software for early diagnosis. Moreover, the prevailing sophisticated level of healthcare facilities in the European region has also led to the huge growth of market in the region.  

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Europe Lung Cancer Screening Software Market Share Analysis

Europe lung cancer screening software market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are PenRad Technologies Inc., Koninklijke Philips N.V, Volpara Health Limited, Thynk Health, Nuance Communications, Inc., Siemens Healthcare GmBH, MyCareWare, Inc., MagView, MeVis Medical Solutions AG, Canon Medical Informatics, Inc., General Electric Company, Epic Systems Corporation, Lungview, Eon, Medtronic, Coreline Soft, Co., Ltd., Optellum Ltd, HealthMyne, Oncocyte Corporation, Genesystem, REVEALDX, FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Median Technologies, AstraZeneca, and Aidence.com among others.

SKU-

TABLE 1 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 2 EUROPE CLOUD BASED SOLUTIONS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 3 EUROPE ON-PREMISE SOLUTIONS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4 EUROPE WEB BASED SOLUTIONS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 5 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 6 EUROPE LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7 EUROPE LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 8 EUROPE LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 9 EUROPE LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 10 EUROPE NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 11 EUROPE NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 12 EUROPE DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 13 EUROPE DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 14 EUROPE PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 15 EUROPE PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 16 EUROPE LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 17 EUROPE LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 18 EUROPE PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 19 EUROPE PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 20 EUROPE STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 21 EUROPE STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 22 EUROPE SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23 EUROPE SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 24 EUROPE PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 25 EUROPE PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 26 EUROPE AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 27 EUROPE AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 28 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 29 EUROPE COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 30 EUROPE COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 31 EUROPE TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 32 EUROPE TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 33 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 34 EUROPE NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35 EUROPE NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 36 EUROPE SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37 EUROPE SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 38 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 39 EUROPE STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40 EUROPE STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 41 EUROPE INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42 EUROPE INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 43 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 44 EUROPE INSTITUTIONAL IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 45 EUROPE INDIVIDUAL IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 46 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 47 EUROPE ONCOLOGY CENTERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 48 EUROPE HOSPITALS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 49 EUROPE AMBULATORY SURGICAL CENTERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 50 EUROPE OTHERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 51 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 52 EUROPE DIRECT TENDERS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 53 EUROPE THIRD PARTY DISTRIBUTOR IN LUNG CANCER SCREENING SOFTWARE MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 54 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 55 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 56 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 57 EUROPE LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 58 EUROPE LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 59 EUROPE NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 60 EUROPE DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 61 EUROPE PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 62 EUROPE LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 63 EUROPE PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 64 EUROPE STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 65 EUROPE SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 66 EUROPE PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 67 EUROPE AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 68 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 69 EUROPE COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 70 EUROPE TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 71 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 72 EUROPE NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 73 EUROPE SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 74 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 75 EUROPE STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 76 EUROPE INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 77 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 78 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 79 EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 80 GERMANY LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 81 GERMANY LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 82 GERMANY LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 83 GERMANY LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 84 GERMANY NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 85 GERMANY DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 86 GERMANY PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 87 GERMANY LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 88 GERMANY PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 89 GERMANY STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 90 GERMANY SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 91 GERMANY PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 92 GERMANY AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 93 GERMANY LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 94 GERMANY COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 95 GERMANY TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 96 GERMANY LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 97 GERMANY NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 98 GERMANY SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 99 GERMANY LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 100 GERMANY STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 101 GERMANY INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 102 GERMANY LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 103 GERMANY LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 104 GERMANY LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 105 FRANCE LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 106 FRANCE LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 107 FRANCE LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 108 FRANCE LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 109 FRANCE NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 110 FRANCE DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 111 FRANCE PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 112 FRANCE LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 113 FRANCE PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 114 FRANCE STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 115 FRANCE SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 116 FRANCE PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 117 FRANCE AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 118 FRANCE LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 119 FRANCE COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 120 FRANCE TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 121 FRANCE LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 122 FRANCE NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 123 FRANCE SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 124 FRANCE LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 125 FRANCE STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 126 FRANCE INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 127 FRANCE LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 128 FRANCE LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 129 FRANCE LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 130 U.K. LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 131 U.K. LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 132 U.K. LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 133 U.K. LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 134 U.K. NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 135 U.K. DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 136 U.K. PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 137 U.K. LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 138 U.K. PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 139 U.K. STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 140 U.K. SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 141 U.K. PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 142 U.K. AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 143 U.K. LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 144 U.K. COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 145 U.K. TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 146 U.K. LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 147 U.K. NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 148 U.K. SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 149 U.K. LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 150 U.K. STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 151 U.K. INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 152 U.K. LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 153 U.K. LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 154 U.K. LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 155 ITALY LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 156 ITALY LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 157 ITALY LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 158 ITALY LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 159 ITALY NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 160 ITALY DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 161 ITALY PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 162 ITALY LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 163 ITALY PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 164 ITALY STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 165 ITALY SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 166 ITALY PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 167 ITALY AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 168 ITALY LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 169 ITALY COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 170 ITALY TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 171 ITALY LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 172 ITALY NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 173 ITALY SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 174 ITALY LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 175 ITALY STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 176 ITALY INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 177 ITALY LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 178 ITALY LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 179 ITALY LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 180 SPAIN LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 181 SPAIN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 182 SPAIN LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 183 SPAIN LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 184 SPAIN NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 185 SPAIN DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 186 SPAIN PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 187 SPAIN LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 188 SPAIN PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 189 SPAIN STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 190 SPAIN SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 191 SPAIN PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 192 SPAIN AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 193 SPAIN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 194 SPAIN COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 195 SPAIN TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 196 SPAIN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 197 SPAIN NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 198 SPAIN SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 199 SPAIN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 200 SPAIN STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 201 SPAIN INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 202 SPAIN LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 203 SPAIN LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 204 SPAIN LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 205 NETHERLANDS LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 206 NETHERLANDS LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 207 NETHERLANDS LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 208 NETHERLANDS LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 209 NETHERLANDS NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 210 NETHERLANDS DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 211 NETHERLANDS PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 212 NETHERLANDS LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 213 NETHERLANDS PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 214 NETHERLANDS STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 215 NETHERLANDS SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 216 NETHERLANDS PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 217 NETHERLANDS AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 218 NETHERLANDS LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 219 NETHERLANDS COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 220 NETHERLANDS TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 221 NETHERLANDS LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 222 NETHERLANDS NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 223 NETHERLANDS SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 224 NETHERLANDS LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 225 NETHERLANDS STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 226 NETHERLANDS INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 227 NETHERLANDS LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 228 NETHERLANDS LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 229 NETHERLANDS LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 230 RUSSIA LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 231 RUSSIA LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 232 RUSSIA LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 233 RUSSIA LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 234 RUSSIA NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 235 RUSSIA DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 236 RUSSIA PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 237 RUSSIA LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 238 RUSSIA PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 239 RUSSIA STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 240 RUSSIA SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 241 RUSSIA PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 242 RUSSIA AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 243 RUSSIA LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 244 RUSSIA COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 245 RUSSIA TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 246 RUSSIA LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 247 RUSSIA NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 248 RUSSIA SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 249 RUSSIA LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 250 RUSSIA STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 251 RUSSIA INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 252 RUSSIA LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 253 RUSSIA LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 254 RUSSIA LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 255 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 256 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 257 SWITZERLAND LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 258 SWITZERLAND LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 259 SWITZERLAND NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 260 SWITZERLAND DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 261 SWITZERLAND PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 262 SWITZERLAND LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 263 SWITZERLAND PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 264 SWITZERLAND STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 265 SWITZERLAND SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 266 SWITZERLAND PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 267 SWITZERLAND AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 268 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 269 SWITZERLAND COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 270 SWITZERLAND TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 271 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 272 SWITZERLAND NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 273 SWITZERLAND SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 274 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 275 SWITZERLAND STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 276 SWITZERLAND INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 277 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 278 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 279 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 280 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 281 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 282 SWITZERLAND LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 283 SWITZERLAND LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 284 SWITZERLAND NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 285 SWITZERLAND DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 286 SWITZERLAND PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 287 SWITZERLAND LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 288 SWITZERLAND PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 289 SWITZERLAND STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 290 SWITZERLAND SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 291 SWITZERLAND PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 292 SWITZERLAND AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 293 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 294 SWITZERLAND COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 295 SWITZERLAND TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 296 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 297 SWITZERLAND NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 298 SWITZERLAND SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 299 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 300 SWITZERLAND STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 301 SWITZERLAND INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 302 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 303 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 304 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 305 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

TABLE 306 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 307 SWITZERLAND LUNG CANCER SCREENING RADIOLOGY SOLUTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 308 SWITZERLAND LUNG CANCER SCREENING PATIENT MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 309 SWITZERLAND NODULE MANAGEMENT SOFTWARE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 310 SWITZERLAND DATA COLLECTION AND REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 311 SWITZERLAND PATIENT COORDINATION AND WORKFLOW IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 312 SWITZERLAND LUNG NODULE COMPUTER AIDED DETECTION IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 313 SWITZERLAND PATHOLOGY AND CANCER STAGING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 314 SWITZERLAND STATISTICAL AUDIT REPORTING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 315 SWITZERLAND SCREENING PACS IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 316 SWITZERLAND PRACTICE MANAGEMENT IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 317 SWITZERLAND AUDIT LOG TRACKING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 318 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 319 SWITZERLAND COMPUTER-ASSISTED SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 320 SWITZERLAND TRADITIONAL SCREENING IN LUNG CANCER SCREENING SOFTWARE MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 321 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 322 SWITZERLAND NON-SMALL CELL LUNG CANCER (NSCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PRODUCT TYPE, 2020-2029 (USD THOUSAND)

TABLE 323 SWITZERLAND SMALL CELL LUNG CANCER (SCLC) IN LUNG CANCER SCREENING SOFTWARE MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 324 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 325 SWITZERLAND STANDALONE IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 326 SWITZERLAND INTEGRATED IN LUNG CANCER SCREENING SOFTWARE MARKET, BY PLATFORM, 2020-2029 (USD THOUSAND)

TABLE 327 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY PURCHASE MODE, 2020-2029 (USD THOUSAND)

TABLE 328 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 329 SWITZERLAND LUNG CANCER SCREENING SOFTWARE MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 330 REST OF EUROPE LUNG CANCER SCREENING SOFTWARE MARKET, BY MODE OF DELIVERY, 2020-2029 (USD THOUSAND)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Europe Lung Cancer Screening Software Market value is expected USD 27,518.34 thousand by 2029.
The Europe Lung Cancer Screening Software Market is to grow at a CAGR of 19.6% during the forecast by 2029.
The major players operating in the Europe Lung Cancer Screening Software Market are PenRad Technologies Inc., Koninklijke Philips N.V, Volpara Health Limited, Thynk Health, Nuance Communications, Inc., Siemens Healthcare GmbH, MyCareWare, Inc., MagView, MeVis Medical Solutions AG, Canon Medical Informatics, Inc., General Electric Company, Epic Systems Corporation, Lungview, Eon, Medtronic, Coreline Soft Co., Ltd., Optellum Ltd, HealthMyne, Oncocyte Corporation, Genesystem, REVEALDX, FUJIFILM Holdings Corporation, F. Hoffmann-La Roche Ltd, Median Technologies, AstraZeneca, and Aidence.com.
The major countries covered in the Europe Lung Cancer Screening Software Market are Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium and rest of Europe.

BROWSE RELATED REPORTS

Global Lung Cancer Screening Software Market – Industry Trends and Forecast to 2031
Middle East and Africa Lung Cancer Screening Software Market – Industry Trends and Forecast to 2029
Asia-Pacific Lung Cancer Screening Software Market – Industry Trends and Forecast to 2029
North America Lung Cancer Screening Software Market – Industry Trends and Forecast to 2029
U.S. Lung Cancer Screening Software Market – Industry Trends and Forecast to 2030

BROWSE RELATED Blogs

Lung Cancer Screening Software in Improving Patient Outcomes
U.S. Lung Cancer Screening Software is Expected to Grow at 19.1% CAGR in the Forecast Period of 2020 to 2027

BROWSE RELATED Press Release

Lung Cancer: The Leading Cancer Killer for Both Men and Women in America
Advanced Lung Cancer Detection: Unveiling Innovative Lung Cancer Screening Software
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries

Buy Now
Request for TOC Speak to Analyst Inquire Before Buying Free Sample Report
Advance Formative Research Customization Request for bulk Reports

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials

David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,

Dear Ricky,
I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.

Image
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions

Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.

Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.

Image
Business Intelligence and Analytics,
Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst,
Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director,
Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO,
A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director,
Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager,
Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations,
GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst,
Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager,
Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment
MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer
Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro
Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future